2016 | 2015 | 2014 | 2013
DateTitle 
December 04, 2016Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi® (ruxolitinib)
- Long-term treatment with Jakafi prolonged survival compared to controls - Data suggest that earlier treatment with Jakafi may improve survival advantage for patients with myelofibrosis (MF) WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 4, 2016-- Incyte Corporation (Nasdaq:INCY) today announces an exploratory pooled analysis of data from the five-year follow-up of the Phase 3 COMFORT-I and COMFORT-II trials which further supports previously... 
Printer Friendly Version
November 14, 2016New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients
Three post-hoc analyses of two phase 3 studies showed improvements in rheumatoid arthritis symptoms in patients irrespective of age, BMI and number of previously used conventional synthetic DMARDsINDIANAPOLIS, Nov. 14, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced new data analyses of two phase 3 trials, RA-BUILD and RA-BEAM, showing that baricitinib treatment resulted in improvements in rheumatoid arthritis (RA) symptoms across a di... 
Printer Friendly Version
November 14, 2016Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes
- Significant improvement in joint pain, severity of morning joint stiffness and tiredness with baricitinib compared to placebo, were seen as early as day 3 - Post-hoc analysis of two phase 3 studies shows significantly improved joint pain, severity of morning joint stiffness and tiredness compared to adalimumab, within 3 weeks of treatment in patients with rheumatoid arthritis who had inadequate response to conventional synthetic DMARDs, including methotrexateINDIANAPOLIS, Nov. 14, 2016 /PRNews... 
Printer Friendly Version
November 03, 2016More Than 20 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 58th Annual ASH Meeting
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 3, 2016-- Incyte Corporation (Nasdaq: INCY) announces that more than 20 abstracts including data from its ongoing clinical development program for Jakafi® (ruxolitinib) and its small molecule development programs targeting JAK1, LSD1 and PI3Kδ will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting 2016 in San Diego, California from December 3-6, 2016. “We are pleased to... 
Printer Friendly Version
November 02, 2016New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo
Phase 3 trial results published in Annals of the Rheumatic Diseases demonstrate baricitinib's significant efficacy in patients with inadequate response to conventional and biologic DMARDs INDIANAPOLIS, Nov. 2, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data from RA-BEACON - a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA) - showed baricitinib demonstrated significant... 
Printer Friendly Version
November 02, 2016Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 2, 2016-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016 at 11:30 am (EST) in New York. The presentation will be webcast live and can be accessed at www.incyte.com in the Investors section under “Events and Presentations”. Investors interested in listening to the live webcast should log on before the ... 
Printer Friendly Version
November 01, 2016Incyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs
$224 million of 2016 third-quarter net product revenues from Jakafi® (ruxolitinib), representing 39 percent growth over the same period last year Jakafi included as a recommended treatment for patients with myelofibrosis in the NCCN® Guidelines for myeloproliferative neoplasms (MPNs) Updated Phase 1 data from ECHO-202 reinforced durability of anti-tumor response in patients with advanced or metastatic ... 
Printer Friendly Version
October 14, 2016Incyte to Report Third Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 14, 2016-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2016 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, November 1, 2016. The schedule for the press release and conference call/webcast is as follows:   •   ... 
Printer Friendly Version
October 07, 2016Additional Phase 1 Data from ECHO-202 Reinforce Durability of Response in Patients with Treatment-naive Advanced or Metastatic Melanoma Treated with Epacadostat in Combination with Keytruda® (pembrolizumab)
Updated data published at ESMO to be discussed on Incyte investor conference call and webcast today, 7 October, at 14:00 CET / 8:00 a.m. ET WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 7, 2016-- Incyte Corporation (Nasdaq:INCY) today announced that updated data from the Phase I portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with pembrolizumab (Keytruda®)*, Merck’s ... 
Printer Friendly Version
September 28, 2016Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda® (Pembrolizumab)
Incyte’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy is well-tolerated and demonstrates durable clinical response in patients with treatment-naïve advanced melanoma WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 28, 2016-- Incyte Corporation (Nasdaq: INCY) today announced that the European Society for Medical Oncology (ESMO) has published an abstract (#1110PD) containing updated data from the Phase 1 portion of the ECHO-202 trial eva... 
Printer Friendly Version
September 27, 2016NCCN Guidelines® Recommend Jakafi® (ruxolitinib) for the Treatment of Myelofibrosis
Treatment guidelines for myeloproliferative neoplasms (MPNs) focused on the treatment of myelofibrosis (MF), a rare blood cancer, published today WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 27, 2016-- Incyte Corporation (Nasdaq: INCY) today announced that its first-in-class JAK1/JAK2 inhibitor, Jakafi® (ruxolitinib), has been included as a recommended treatment in the latest National Comprehensive Cancer Network® (NCCN®) Clinical Practice G... 
Printer Friendly Version
September 08, 2016Incyte Supports Those Affected by Rare Blood Cancers on MPN Awareness Day and Throughout Blood Cancer Awareness Month
MPN Landmark Survey Underscores Burden of Disease in MPN Patients and the Importance of Raising Awareness Today and Throughout the Month of September WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 8, 2016-- Incyte Corporation calls for increased awareness and support for those living with myeloproliferative neoplasms (MPNs) today, MPN Awareness Day, and throughout September, Blood Cancer Awareness Month. MPNs are a closely related group of rare, prog... 
Printer Friendly Version
August 30, 2016Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 30, 2016-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2016 at 11:05 am (EDT) in New York; and LEERINK Partners Rare Disease & Immuno-Oncology Roundtable on Thursday, September 29, 2016 at 3:45 pm (EDT) in N... 
Printer Friendly Version
August 25, 2016Forbes Magazine Names Incyte to its List of World’s Most Innovative Companies for Second Consecutive Year
Company ranked 4th in 2016 and in Top 10 for Second Year Running WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 25, 2016-- Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 4th on Forbes magazine’s 2016 list of the World’s Most Innovative Companies. Incyte, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, is advancing an innovative and diverse portfolio of large and... 
Printer Friendly Version
August 09, 2016Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs
$208 million of 2016 second-quarter net product revenues from Jakafi® (ruxolitinib), representing 46 percent growth over the same period last year ECHO-301, the first Phase 3 trial evaluating epacadostat, now underway in combination with pembrolizumab as first-line treatment of patients with advanced or metastatic melanoma New Phase 3 clinical data from COMFORT-I in myelofibrosis and RESPONSE-2 in poly... 
Printer Friendly Version
July 19, 2016Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016
Data from the Phase 1 portion of the ECHO-202 study evaluating epacadostat in combination with Keytruda® (pembrolizumab) to be highlighted as a poster discussion WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 19, 2016-- Incyte Corporation (Nasdaq:INCY) announces that updated data from the Phase 1 portion of the ECHO-202/KEYNOTE-037 trial has been accepted for a poster discussion at the European Society for Medical Oncology (ESMO) Annual Congress 2016... 
Printer Friendly Version
July 14, 2016Incyte to Report Second Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 14, 2016-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter 2016 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, August 9, 2016. The schedule for the press release and conference call/webcast is as follows:     ... 
Printer Friendly Version
June 23, 2016FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease (GVHD)
WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 23, 2016-- Incyte Corporation (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ruxolitinib (Jakafi®) for the treatment of patients with acute graft-versus-host disease (GVHD). There are currently no approved treatments for patients with acute GVHD. Breakthrough Therapy Designation is designed to expedite the development a... 
Printer Friendly Version
June 22, 2016Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study
Pivotal trial to evaluate epacadostat in combination with Keytruda® (pembrolizumab) as first-line treatment for patients with advanced or metastatic melanoma WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 22, 2016-- Incyte Corporation (Nasdaq: INCY) today announced that the first patient has been treated in the ECHO-301 study—a Phase 3 trial evaluating epacadostat, Incyte’s investigational, highly potent and selective oral IDO1 inhibitor, in combinat... 
Printer Friendly Version
June 22, 2016Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-GITR agonist antibody INCAGN1876. The trial is being conducted by, and in collaboration with, Incyte Corporation.The open-label, dose-escalation portion of the trial will evaluate the safety and tolerabilit... 
Printer Friendly Version
June 10, 2016New Phase 3 Data Show Jakafi® (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera (PV)
62 percent of PV patients treated with Jakafi achieved hematocrit control without phlebotomy, compared to 18 percent of patients treated with best available therapy RESPONSE-2 data complements previous findings from RESPONSE, reinforcing Jakafi is effective in PV patients with or without an enlarged spleen WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 10, 2016-- Incyte Corporation (Nasdaq: INCY) today announced new ... 
Printer Friendly Version
June 09, 2016Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)
Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate - the current standard of care - and adalimumab (Humira®)* INDIANAPOLIS, June 9, 2016 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that in two phase 3 trials patients with rheumatoid arthritis (RA) treated with baricitinib reported significant improvements in quality of life sympt... 
Printer Friendly Version
June 09, 2016Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs
Patients from pivotal 24-week phase 3 trial RA-BUILD who entered long-term extension study, RA-BEYOND, demonstrate baricitinib continues to inhibit radiographic progression of structural joint damage over one yearINDIANAPOLIS, June 9, 2016 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study, RA-BEYOND, was presented at the Annual European Congress of Rheumatology (EULAR 2016) in London. The findings d... 
Printer Friendly Version
June 06, 2016Five-year Results from Phase 3 Study of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis (MF)
- COMFORT-I data demonstrate that treatment with Jakafi resulted in a 31 percent reduction in the risk of death and sustained durable spleen volume reduction in patients with MF - These five-year data support previously published findings for Jakafi WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 6, 2016-- Incyte Corporation (Nasdaq:INCY) today announces five-year data from the Phase 3 COMFORT-I study evaluating the long-term safety and effi... 
Printer Friendly Version
June 01, 2016Incyte and Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance
Collaboration focuses on basic and translational research involving novel therapeutic approaches for hematologic malignancies WILMINGTON, Del. & TAMPA, Fla.--(BUSINESS WIRE)--Jun. 1, 2016-- Incyte Corporation (Nasdaq: INCY) and Moffitt Cancer Center today announced that they have entered into a research support and collaboration agreement, whereby Incyte has agreed to provide funding to conduct three new Moffitt Cancer Center research prog... 
Printer Friendly Version
May 31, 2016Incyte Announces the Launch of the Incyte Charitable Giving Foundation
Foundation to Fund Oncology Patient Support and Resources and Community Partnerships in Delaware WILMINGTON, Del.--(BUSINESS WIRE)--May 31, 2016-- Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company, today announced the launch of the Incyte Charitable Giving Foundation, which will provide charitable donations to publicly-funded 501(c)(3) tax-exempt nonprofit organizations serving the needs of communities in Delaware. ... 
Printer Friendly Version
May 19, 2016Incyte Highlights Jakafi® (ruxolitinib) and Capmatinib Abstracts to be Presented at the 2016 ASCO and EHA Annual Meetings
WILMINGTON, Del.--(BUSINESS WIRE)--May 19, 2016-- Incyte Corporation (Nasdaq: INCY) announces that more than 20 abstracts featuring its clinical development candidates will be presented at the 2016 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings. These conferences will take place from June 3–7, 2016 (ASCO) in Chicago, Illinois and June 9–12, 2016 (EHA) in Copenhagen, Denmark. “The abst... 
Printer Friendly Version
May 18, 2016Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--May 18, 2016-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 2:00 pm (EDT) in New York; and Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016 at 2:00 pm (PDT) / 5:00 pm (EDT) in Rancho Pa... 
Printer Friendly Version
May 09, 2016Incyte First Quarter Financial Results Conference Call and Webcast
WILMINGTON, Del.--(BUSINESS WIRE)--May 9, 2016-- Incyte Corporation (Nasdaq: INCY) today confirms the details for its first quarter 2016 financial results conference call and webcast for 10:00 a.m. ET on Monday, May 9, 2016. The conference ID number included in this morning’s press releases was incorrect. The schedule for the press release and conference call/webcast is as follows: ... 
Printer Friendly Version
May 09, 2016Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe
Incyte to Accelerate the Expansion of its European Organization to Optimize the Potential of Future Product Launches in Europe ARIAD to Receive $140 Million Upfront Payment, Plus Tiered Royalties on European Sales of Iclusig and Potential Milestones on Future Indications for Iclusig WILMINGTON, Del. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2016-- Incyte Corporation (Nasdaq:INCY) and ARIAD Pharmaceuticals... 
Printer Friendly Version
May 09, 2016Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
$183 million of 2016 first-quarter net product revenues from Jakafi® (ruxolitinib), representing 59 percent growth over the same period last year. Full year Jakafi net product revenue guidance increased from a range of $800-815 million to a range of $815-830 million. Recent agreements with Lilly and Novartis allow development of ruxolitinib for the treatment of graft versus host disease (GVHD); U.S. pivotal trial expected to b... 
Printer Friendly Version
April 28, 2016Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 28, 2016-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May 11, 2016 at 1:00 pm (PDT) in Las Vegas; and UBS Global Healthcare Conference on Monday, May 23, 2016 at 1:00 pm (EDT) in New York The p... 
Printer Friendly Version
April 15, 2016Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio
Sustained R&D productivity has generated 14 clinical development candidates against 11 discrete molecular targets Diverse immuno-oncology and targeted cancer therapy portfolios comprised of both large and small molecule therapies Live webcast presentation from AACR taking place Sunday, April 17, 2016 at 7:00 p.m. CDT / 8:00 p.m. EDT WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 15, 2016-- Incyte ... 
Printer Friendly Version
April 14, 2016Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 14, 2016-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter 2016 financial results conference call and webcast for 10:00 a.m. ET on Monday, May 9, 2016. The schedule for the press release and conference call/webcast is as follows:       ... 
Printer Friendly Version
April 06, 2016Incyte Acquires Rights from Lilly to Develop and Commercialize Ruxolitinib (Jakafi®) for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
Pivotal development program for ruxolitinib in GVHD expected to begin in 2016 Novartis agreement amended to include development and commercialization rights for ruxolitinib in GVHD outside of the U.S. WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 6, 2016-- Incyte Corporation (Nasdaq:INCY) today announced it has acquired the rights to develop and commercialize ruxolitinib (Jakafi®), its proprietary JAK1/JAK2 inhibitor, f... 
Printer Friendly Version
March 31, 2016Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis Who Had Inadequate Response to Biologics
Pivotal RA-BEACON Study Published in New England Journal of Medicine INDIANAPOLIS, March 31, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a once-daily oral treatment currently under regulatory review for the treatment of moderate-to-severe rheumatoid arthritis (RA) — were published today in the New England Journal of Medicine. The study met its pr... 
Printer Friendly Version
March 16, 2016Incyte’s Immuno-oncology and Targeted Therapy Portfolio to be Featured at the AACR Annual Meeting 2016
Ten abstracts selected for presentation from the Company’s GITR agonist, OX40 agonist, LSD1 inhibitor, BRD (BET) inhibitor, PI3Kδ inhibitor and JAK1 inhibitor programs WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 16, 2016-- Incyte Corporation (Nasdaq: INCY) announces that ten abstracts featuring data from its emerging development portfolio will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2016 in New O... 
Printer Friendly Version
February 29, 2016Incyte Joins Patient Organizations Worldwide in Recognition of Rare Disease Day 2016 to Make Patient Voices Heard
February 29, 2016, commemorates International Rare Disease Day Incyte Corporation supports efforts to raise awareness and improve diagnosis and treatment for the nearly 200,000 people in the United States with MPNs, a group of rare blood cancers MPN Heroes® 2016 nominations now open for submission WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 29, 2016-- Incyte Corporation (Nasdaq: INCY) joins the European Organization for Rare... 
Printer Friendly Version
February 16, 2016Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 16, 2016-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen and Company 36th Annual Health Care Conference on Monday, March 7, 2016 at 1:20 pm (EST) in Boston; and Barclays Capital Global Healthcare Conference on Wednesday, March 16, 2016 at 9:30 am (EDT) in Miami ... 
Printer Friendly Version
February 11, 2016Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs
$182 million of 2015 fourth-quarter net product revenues from Jakafi® (ruxolitinib), representing 72 percent growth over the same period last year and $601 million of 2015 full-year net product revenues from Jakafi, representing 68 percent growth over last year 2016 guidance for Jakafi net product revenues in the range of $800 million to $815 million, reflecting expectations for continued growth in underlying demand in myelofi... 
Printer Friendly Version
February 11, 2016Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 11, 2016-- Incyte Corporation (Nasdaq: INCY) announced today its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer. The decision to stop the study was made after a planned interim analysis of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a suffic... 
Printer Friendly Version
January 27, 2016Incyte Announces Decision to Stop Phase 2 Sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 27, 2016-- Incyte Corporation (Nasdaq: INCY) announced today that the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib in patients with relapsed or refractory metastatic colorectal cancer (CRC) and high C-reactive protein (CRP) will be stopped early. The decision to stop the sub-study was made after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus reg... 
Printer Friendly Version
January 21, 2016Incyte to Report Fourth Quarter/Year-End Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 21, 2016-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter 2015 financial results conference call and webcast for 10:00 a.m. ET on Thursday, February 11, 2016. The schedule for the press release and conference call/webcast is as follows:       ... 
Printer Friendly Version
January 19, 2016Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis
INDIANAPOLIS, Jan. 19, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that Lilly has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis (RA). As a result, Incyte will receive a milestone payment of $35 million from Lilly related to the NDA submission. If baricitinib ... 
Printer Friendly Version
January 11, 2016Incyte Presents Significant Progress in its Development Portfolio
Rapidly advancing portfolio with 13 development molecules being investigated as monotherapy and in combination across multiple indications Two new development molecules—an LSD1 inhibitor and an anti-GITR agonist—added to the portfolio and expected to enter the clinic in first-half of 2016 Rich news flow from pivotal and proof-of-concept programs expected in 2016 Webcast present... 
Printer Friendly Version
January 11, 2016Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 11, 2016-- Incyte Corporation (Nasdaq:INCY) and AstraZeneca (NYSE:AZN) today announced a new collaboration to evaluate the efficacy and safety of Incyte’s Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in combination with AstraZeneca’s next generation epidermal growth factor receptor (EGFR) inhibitor, Tagrisso® (osimertinib). The combination will be assessed as a second-line treatment for patients wit... 
Printer Friendly Version
RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet